-
A Mature Capital Structure Positions Bio-IT Startups For Success
Bio-IT World Contributed Commentary | By establishing a mature capital structure reflecting a healthy balance of both equity and debt, early-stage bio-IT companies can project long-term strength and vision that helps to favorably position them with their stakeholders.
Dec 6, 2018
-
GSK Bags Tesaro For $5B As It Leaps Back Into Commercial Oncology, Beefs Up Cancer Drug Pipeline
Endpoints News | GlaxoSmithKline has struck a deal to buy Tesaro in a $5.1 billion deal that will vault the pharma giant into the commercial oncology market as it stakes out a big new role for itself in the booming cancer field.
Dec 5, 2018
-
OmniTier Debuts CompStor Novos Platform For De Novo Assembly-Based Variant Calling
Bio-IT World News Brief | OmniTier has debuted the CompStor Novos platform for de novo assembly-based variant calling in whole genome sequencing applications.
Dec 5, 2018
-
Despite CRISPR Baby Controversy, Harvard University Will Begin Gene-Editing Sperm
MIT Technology Review | Even as a furious debate broke out in China over gene-edited babies, some scientists in the US are also hoping to improve tomorrow's children.
Nov 30, 2018


